Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dengue is with about 100 million cases each year a major public health problem in the tropics. This research aims to understand how the Dengue virus interacts with the innate immune response. Results are relevant for the design of a future anti-viral treatment or vaccine that are currently not available.

Q: What is Dengue infection?

KL: Dengue is, with about 100 million cases each year, a major public health problem in the tropical and sub tropical areas of the world. It is caused by any of the four slightly different sub types of the Dengue virus, and the virus actually gets transmitted by mosquitoes. The severity of the disease can range from the relatively mild Dengue fever, with a high fever and debilitating muscle and joint pain and nausea, to the more severe forms like Dengue Hemorrhagic Fever and Dengue shock syndrome. Patients suffering from the more severe forms do, on top of the normal symptoms, develop quite severe oedema or bleedings due to leaky blood vessels. Infants, children as well as adults can be diagnosed with Dengue but it is quite striking that the most severe forms of the disease are mostly affecting children. Although Dengue is such a big problem, in the mean time nearly half of the world's population is living at risk of infection, there is still no vaccine available and we also don't have any anti-viral drugs for treatment.

Q: What is the effect of Dengue on our innate immune system?

KL: The innate immune system is a key component of our body's immune response. It is the first line of defence and it senses incoming pathogens and then sets the stage for all subsequent immune responses. It has great regulatory potential. It's very important in Dengue because the virus infects innate immune cells and replicates in them. On top of this it is a bit of a special situation for Dengue because there is a growing body of evidence that the immune system itself, rather than the virus, is causing the symptoms. So this phenomenon is called immunopathology. We are now trying to investigate how the virus is interacting with the innate immune cells so we are looking at very early molecular events in innate immune cells upon Dengue virus encounter. Our aim is to understand how and actually into which direction the virus is trying to push the immune response. So that patients with Dengue actually finally end up with immunopathology in contrast to patients with a lot of other viral infections.

Q: And could this research lead to a vaccine or better treatment?

KL: A lot of different factors are actually important or play a role in the outcome of the Dengue infection, for example the genetic outfit of the host or the virulence of the infecting viral strain. But most notably the immune response seems to be responsible. By stimulating the immune response in an inappropriate way using a vaccine the outcome of the subsequent Dengue infection could even be worse so we have to be really careful with this. Therefore a basic understanding of immune processes in Dengue is vital for the development of a vaccine and also for the identification of a new drug targets. Our work has the potential to provide key information regarding these processes.

Q: What are the most important lines of research that have developed over the past five or ten years?

KL: It has been quite important to the field that Dengue has finally been recognised as an important and re-emerging disease; case numbers are dramatically on the rise. There have been suggestions that due to global warming the geographical distribution of the mosquito might increase and hence the Dengue prevalence. But these facts have broadly been acknowledged by now. In addition the field has been hampered for a long time by the lack of suitable model systems. Some studies into this improved the situation enormously now allowing research into diverse directions and we are now able to address a much broader range of questions.

Q: How does your research fit into translational medicine within the department?

KL: I think our work fits in quite well with work that is done by other groups in the department. For example we are collaborating with Professors Cameron Simmons and Jeremy Farrar at the Oxford University Clinical Research Unit at Ho Chi Minh City in Vietnam. Through this collaboration we have access to Dengue patient samples that help us to confirm the results that we obtained in the laboratory. We can then use those results; they can be translated and actually used for the design of potential new drugs or a vaccine.

Kerstin Luhn

Dengue virus infection and innate immune cells

Dr Kerstin Luhn is investigating the effect of Dengue virus infection on innate immune cells to understand why Dengue, unlike other viral infections, is associated with high levels of immunopathology. An in vitro Dengue model is used and results are confirmed with Dengue patient samples from a cohort in Vietnam.

This podcast presents the research done by Dr Luhn whilst working in the Nuffield Department of Medicine. Dr Kerstin Luhn now works at the Radcliffe Department of Medicine.

More podcasts related to Ex-faculty podcasts

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.